Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Lung Neoplasms 12Carcinoma, Non-Small-Cell Lung 8Drug-Related Side Effects and Adverse Reactions 7Radiation Injuries 4Ovarian Neoplasms 4Carcinoma, Ovarian Epithelial 4Small Cell Lung Carcinoma 2Sarcoma 2Neurotoxicity Syndromes 2Head and Neck Neoplasms 2Breast Neoplasms 2Waldenstrom Macroglobulinemia 1Urinary Bladder Neoplasms 1Testicular Neoplasms 1Testicular Germ Cell Tumor 1Squamous Cell Carcinoma of Head and Neck 1Sarcoma, Kaposi 1Prostatic Neoplasms 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pneumonia 1Osteosarcoma 1Neuroectodermal Tumors, Primitive, Peripheral 1Neoplasms, Unknown Primary 1Mesothelioma, Malignant 1Mesothelioma 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Large-Cell, Immunoblastic 1

Interventions

Immunonutrition Diet 1Amifostine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Esophagitis × Amifostine × Thoracic × Clear all
NCT00081315 2007-08-21

Subcutaneous Amifostine (Ethyol®) in the Prevention of Radiochemotherapy-Induced Esophagitis and Pneumonitis in Patients With Unresectable Non-Small Cell Lung Cancer

MedImmune LLC

Phase 2 Completed
130 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Esophagitis, Pneumonia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡